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Los Angeles, California; and New York, New YorkRecent literature has argued the superiority of radial access compared with femoral access for percutaneous
coronary intervention (PCI) in acute coronary syndrome (ACS). Three particular trialsdRIVAL (Radial Versus
Femoral Access for Coronary Intervention), RIFLE-STEACS (Radial Versus Femoral Randomized Investigation
in ST-Elevation Acute Coronary Syndrome), and STEMI-RADIAL (ST Elevation Myocardial Infarction Treated
by Radial or Femoral Approach–Randomized Multicenter Study Comparing Radial Versus Femoral Approach
in Primary PCI)ddemonstrated lower rates of bleeding and vascular complications with the transradial
approach. Bleeding is a major independent predictor of negative long-term outcomes including death,
predisposes patients to transfusions, and attenuates the ability to administer cardioprotective post-
procedural anticoagulation. These trials, however, employed suboptimal antithrombotic practices. Namely,
the dose of heparin and percent of patients on glycoprotein IIb/IIIa inhibitors were unnecessarily high, and
a paucity of patients were on bivalirudin, which decreases bleeding and improves outcomes compared
with heparin and glycoprotein IIb/IIIa inhibitors. The use of larger gauge catheters in femoral access
patients predisposed them to major bleeding and its subsequent complications. In addition, these trials
were carried forth in high-volume transradial centers, further limiting the ability to generalize the ﬁndings
to most PCI centers. These are important considerations especially for high-risk and ACS patients, in
whom the negative implications of major bleeding are even greater. Without an optimized design,
the applications of the trial ﬁndings are uncertain. Ultimately, a trial comparing femoral versus radial
access in patients on bivalirudin, potent oral antiplatelet medication, and without adjunctive glycoprotein
IIb/IIIa inhibitors is needed to assess outcomes based on access site alone. (J Am Coll Cardiol Intv
2013;6:1149–52) ª 2013 by the American College of Cardiology FoundationThe beneﬁts of early invasive treatment with
percutaneous coronary intervention (PCI) in pa-
tients presenting with acute coronary syndrome
(ACS) are well accepted (1,2). However, recent
literature has challenged the common practice of
attaining access via the femoral artery, arguing the
superiority of radial access in terms of bleeding
and mortality, and calling for a paradigm shift in
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2, 2013, accepted August 14, 2013.the published evidence favoring radial access is
compelling, there exist fundamental limitations in
the methodology of these studies. Namely, the
administration of antithrombotic agents was either
excessive, inappropriate, or both. Here, we offer
insight into and special consideration to these trials
with reconsideration of the femoral approach.
Trials Comparing Radial and Femoral
Access in Acute Coronary Syndrome
The RIVAL trial. The RIVAL (Radial Versus
Femoral Access for Coronary Intervention) trial was
initiated as a substudy of the CURRENT-OASIS 7
(Clopidogrel Optimal Loading Dose Usage to
Reduce Recurrent Events/Optimal Antiplatelet
Strategy for Interventions) trial (which investigated
standard vs. high-dose aspirin and clopidogrel
in ACS patients for early invasive intervention),
Table 1. Summary of Clinical Trials Comparing TRI and TFI
Trial
RIVAL
(N ¼ 7,021)
RIFLE-STEACS
(N ¼ 1,001)
STEMI-RADIAL
(N ¼ 707)
Patients, TRI/TFI 3,507/3,514 500/501 348/359
Type of patients ACS patients:
STEMI 27.9%
NSTEMI 27.1%
UA 45%
STEMI patients STEMI patients
Heparin, IU/kg */* 70/71 103/105
GP IIb/IIIa inhibitors 25.3%/24.0% 67.4%/69.9% 45%/45%
Bivalirudin 2.2%/3.1% 8.0%/7.2% */*
Catheter, 6-F 91.8%/87.0% 90.8%/81.4% 100%/99.8%
Major bleeding 0.8%/0.9%
(p ¼ 0.87)
7.8%/12.2%
(p ¼ 0.026)
1.4%/11.0%
(p ¼ 0.0001)
MACE 2.7%/4.6%
(p ¼ 0.031)
7.2%/11.4%
(p ¼ 0.029)
3.5%/4.2%
(p ¼ 0.7)
Mortality 1.3%/3.2%
(p ¼ 0.006)
5.2%/9.2%
(p ¼ 0.02)
2.3%/3.1%
(p ¼ 0.64)
Values are n/n or %/% TRI/TFI, except as indicated. *Data not provided.
ACS ¼ acute coronary syndrome; GP ¼ glycoprotein; MACE ¼ major adverse cardiac events;
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1150with additional patients independently enrolled (Table 1)
(3). Ultimately, 7,021 patients with ACS (unstable angina,
non–ST-segment elevation myocardial infarction, and ST-
segment elevation myocardial infarction [STEMI]) and
planned PCI were randomized to either radial or femoral
access (n ¼ 3,507 and 3,514, respectively) (3). The primary
outcome, deﬁned as the composite of death, MI, stroke,
and non-coronary artery bypass grafting–related major
bleeding at 30 days, was not signiﬁcantly different
between the radial versus femoral approach (3.7% vs. 4.0%,
p ¼ 0.50) (3).
In the subgroup of STEMI patients, the radial access
arm met primary outcome criteria (3.1% vs. 5.2%, p ¼ 0.026)
and was associated with signiﬁcantly lower mortality (1.3%
vs. 3.2%, p ¼ 0.006) (3). Interestingly, bleeding was not
signiﬁcantly different (p ¼ 0.87) (3). Notably, a majority
of patients were a subgroup of the negative CURRENT-
OASIS 7 trial, an important consideration because subgroup
analyses of negative studies are not generally considered
statistically appropriate (10).NSTEMI ¼ non–ST-segment elevation myocardial infarction; RIFLE-STEACS ¼ Radial Versus
Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome trial; RIVAL ¼
Radial Versus Femoral Access for Coronary Intervention; STEMI ¼ ST-segment elevation
myocardial infarction; STEMI-RADIAL ¼ ST Elevation Myocardial Infarction Treated by Radial or
Femoral Approach–Randomized Multicenter Study Comparing Radial Versus Femoral Approach
in Primary PCI trial; TFI ¼ transfemoral intervention; TRI ¼ transradial intervention;
UA ¼ unstable angina.
Abbreviations
and Acronyms
ACS = acute coronary
syndrome
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarction
TFI = transfemoral
interventionThe RIFLE-STEACS trial. The
RIFLE-STEACS (Radial Versus
Femoral Randomized Investiga-
tion in ST-Elevation Acute Cor-
onary Syndrome) trial randomized
1,001 STEMI patients to PCI
with radial or femoral access
(n ¼ 500 and 501, respectively).
The primary outcomedcomposite
of cardiac death, stroke, MI, target
lesion revascularization, or bleed-
ing at 30 daysdwas signiﬁcantly
lower in the radial group (13.6% vs.21.0%, p ¼ 0.003) (4). Major adverse cardiac events were also
lower (7.2% vs. 11.4%, p ¼ 0.029) owing mainly to differences
in cardiac death (5.2% vs. 9.2%, p ¼ 0.020) (4). Non-coronary
artery bypass grafting–related major bleeding was reduced with
the radial approach (7.8% vs. 12.2%, p ¼ 0.026), driven by
a 62% reduction in access-site bleeding (2.6% vs. 6.8%,
p ¼ 0.002) (4).
The STEMI-RADIAL trial. In the STEMI-RADIAL (ST
Elevation Myocardial Infarction Treated by Radial or
Femoral Approach–Randomized Multicenter Study
Comparing Radial Versus Femoral Approach in Primary
PCI) trial, patients with STEMI undergoing primary PCI
were randomized to radial or femoral access (n ¼ 348 and
359, respectively). The primary outcome of bleeding or
access-site complications was measured at 30 days. Radial
access was associated with 80% less bleeding and access-site
complications compared with femoral access (1.4% vs.
7.2%, p ¼ 0.0001) (5). The composite rate of adverse
events was also signiﬁcantly lower in the radial group
(4.6% vs. 11.0%, p ¼ 0.0028) (5). However, there was no
difference in major adverse cardiac events (3.5% vs. 4.2%,
TRI = transradial interventionp ¼ 0.7) or mortality (2.3% vs. 3.1%, p ¼ 0.64) between
the 2 groups (5).
Anticoagulation: The Forgotten Variable
Antithrombotic dose. In the United States, as many as 32%
of patients receive antithrombotic doses in excess of guide-
lines (11). In patients with STEMI being referred for
primary PCI, the American College of Cardiology Foun-
dation/American Heart Association guideline recommends
a 50- to 70-IU/kg bolus to achieve an activated clotting time
of 200 to 250 s when use of glycoprotein IIb/IIIa receptor
antagonists are planned and a 70- to 100-U/kg bolus to
achieve an activated clotting time of 250 to 300 s (as
measured by the HemoTec device [Medtronic, Parker,
Colorado]) when no glycoprotein IIb/IIIa inhibitor use
is planned (12). Heparin doses in excess of this have not
been associated with improved pre-procedural patency or
post-procedural outcomes, but have been associated with
greater bleeding (13). The average dose of pre-procedural
heparin was 71 IU/kg in the RIFLE-STEACS trial and,
more egregiously, 104 IU/kg in STEMI-RADIAL, doses
higher than current guideline recommendations when gly-
coprotein IIb/IIIa inhibitors are used because low-dose
heparin is equally effective (4,5,12,13).
Antithrombotic drug. The ACUITY (Acute Catheterization
and Urgent Intervention Triage strategy) trial demonstrated
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1151signiﬁcantly less bleeding with the direct thrombin inhibitor
bivalirudin compared with heparin and glycoprotein IIb/IIIa
inhibitors at 30 days (3.0% vs. 5.7%, p < 0.001) in patients
with ACS undergoing an invasive strategy (14). The
HORIZONS-AMI (Harmonizing Outcomes With
Revascularization and Stents in Acute Myocardial Infarc-
tion) trial, which compared STEMI patients randomized to
heparin plus glycoprotein IIb/IIIa inhibitors or bivalirudin,
reported a 34% reduction in mortality in patients treated
with bivalirudin (p ¼ 0.047), driven by a reduction in major
bleeding of 40% (p < 0.001) that was similarly seen in a
subsequent large meta-analysis (15,16). In both the radial
and femoral arms, a paucity of patients received bivalirudin
(RIVAL: 2.2% and 3.1%, respectively; RIFLE-STEACS:
8.0% and 7.2%, respectively) despite the evidence showing
that bivalirudin attenuates bleeding events by one-half
without additional ischemic complications (3,4,14,15). The
importance of this cannot be ignored; bleeding indepen-
dently predicts ischemic complications, transfusion, and
death (17,18).
Presumably, the differences in bleeding and mortality
relate in part to the aggressive use of glycoprotein IIb/IIIa
inhibitorsdapproximately one-third in the RIVAL trial,
nearly half in the STEMI-RADIAL trial, and over two-
thirds in the RIFLE STEACS trialdpredisposing to
bleeding and vascular complications in the large-caliber
femoral artery in which larger sheaths were used.
Implications and Considerations:
High-Risk Patients, Procedural Characteristics,
and Operator Experience
Lower doses of heparin, decreased use of potent parenteral
antiplatelet agents, and increased use of bivalirudin could
ultimately reduce bleeding and need for transfusions. This
would permit continuation, not only of post-procedural oral
antiplatelet drugs, but also of other cardioprotective agents,
lessening the risk for subsequent cardiac compromise
(a main determinant of mortality in the femoral access
approach). These considerations are particularly relevant in
high-risk ACS patients, in whom the larger femoral artery
may be necessary anyway for device insertion such as an
intra-aortic balloon pump.
Procedural characteristics are also affected by the choice of
access site. Door-to-balloon and ﬂuoroscopy times tend to
be less with the femoral approach, and choice of sheath size
is less restrictive (3–5). Outcomes with vascular closure
devices have evolved over time, but recent meta-analyses
have noted they may safely reduce femoral bleeding, further
reducing the gap in bleeding and mortality outcomes
between access sites (19).
Finally, the prospective randomized trials supporting
the radial approach were all done at high-volume radial
access centers. Indeed, the RIVAL study demonstratedno difference in the lower 2 tertiles of operator experience
(3). This is an important consideration in the United
States, where <7% of PCI procedures are accessed radially
(11,20).
Conclusions
At ﬁrst glance, current studies support the beneﬁts of
radial access PCI in ACS. These conclusions, however, are
drawn from patients on suboptimal antithrombotic regimens
as well as liberal use of potent parenteral antiplatelet
agents. Thus, the inﬂuence of access site alone on outcomes
cannot be accurately measured. Ultimately, a trial comparing
femoral versus radial access in patients treated with
bivalirudin or appropriate doses of heparin, novel P2Y12
receptor inhibitors such as prasugrel or ticagrelor and
without adjunctive glycoprotein IIb/IIIa inhibitors, is
needed to assess outcomes on the basis of access site alone.
The ongoing SAFARI-STEMI (the Safety and Efﬁcacy of
Femoral Access Versus Radial for Primary Percutaneous
Coronary Intervention in ST-Elevation Myocardial
Infarction) trial (NCT01398254) will help shed light into
this particular topic. Until further data emerge, femoral
access with optimal pharmacotherapy should be considered
a safe, viable and time-tested option for PCI access in ACS.
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